EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases

Caihong Yu, Juncheng Wan, Chaoqiao Jin, Changyu Li, Yuqi Jiang, Yongjie Zhou iD, Xudong Qu iD

International Journal of Cancer · 15.07.2026 · 159 (2) · 423-431

DOI: 10.1002/ijc.70405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 25.02.2026. Verfasst von Caihong Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Lung Neoplasms, Chemoembolization, Therapeutic, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Key R&D Program of China, Shanghai Innovative Pharmaceutical and Medical Device Product Application Demonstration Project, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the efficacy and safety of bronchial arterial infusion (BAI) chemotherapy combined with transarterial chemoembolization (TACE) plus systemic therapy in hepatocellular carcinoma (HCC) patients with lung metastases. This study retrospectively analyzed 54 HCC patients with lung metastases who underwent TACE combined with systemic therapy and/or BAI chemotherapy, at initial diagnosis from January 2018 to June 2023. Systemic therapy included targeted agents (apatinib, lenvatinib, and regorafenib, or bevacizumab) and programmed cell death protein 1 (PD‐1) inhibitors (sintilimab, camrelizumab, and tislelizumab). During follow‐up, treatment‐related adverse events were recorded. Progression‐free survival (PFS) was assessed separately for lung metastases and intrahepatic lesions, along with overall survival (OS). Fifty‐four eligible patients with HCC were enrolled, including 32 in the BAI plus TACE and systemic therapy group (BTS group) and 22 in the TACE plus systemic therapy group (TS group). At 3 months post‐treatment, the BTS group showed significantly higher objective response rate of lung metastatic lesions (50.0% vs. 22.7%, p = .043) and disease control rate (DCR) (93.7% vs. 68.2%, p = .013) than the TS group. By study end, DCR remained higher in the BTS group (84.4% vs. 54.5%, p = .016). Median PFS of lung metastatic lesions was 7.1 versus 3.3 months ( p = .004), and median OS was 13.9 versus 7.6 months ( p = .009), both favoring the BTS group. The combination of BAI, TACE, and systemic therapy achieved favorable therapeutic outcomes and acceptable safety in patients with HCC with lung metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsLung NeoplasmsChemoembolization, TherapeuticCarcinoma, HepatocellularAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedInfusions, Intra-ArterialRetrospective StudiesAgedBronchial ArteriesCombined Modality TherapyAdultPhenylurea Compounds

Stichwörter der Autor:innen

bronchial arterial infusion chemotherapyhepatocellular carcinomalung metastasessystemic therapytransarterial chemoembolization

Substanzen

Phenylurea Compounds

Autor:innen und Institutionen

  • Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China.
  • National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Yongjie Zhou, Xudong Qu

Förderung

  • National Key R&D Program of China
  • Shanghai Innovative Pharmaceutical and Medical Device Product Application Demonstration Project
  • National Key Research and Development Program of China

Zitieren

APA

Yu, C., Wan, J., Jin, C., Li, C., Jiang, Y., Zhou, Y., & Qu, X. (2026). Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases. International Journal of Cancer, 159(2), 423-431. https://doi.org/10.1002/ijc.70405

Vancouver

Yu C, Wan J, Jin C, Li C, Jiang Y, Zhou Y, et al. Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases. International Journal of Cancer. 2026;159(2):423-431. doi:10.1002/ijc.70405

BibTeX
@article{Yu2026,
  author = {Yu, Caihong and Wan, Juncheng and Jin, Chaoqiao and Li, Changyu and Jiang, Yuqi and Zhou, Yongjie and Qu, Xudong},
  title = {Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {2},
  pages = {423--431},
  doi = {10.1002/ijc.70405}
}
Kostenlos starten →